Vitiligo associated with ribociclib therapy: a rare case report
HR-positive metastatic breast cancer patients using ribociclib may develop vitiligo, with individual differences (e.g., over one-year incubation as in this case). Combined with prior reports, it suggests a link between ribociclib and vitiligo. Further clinical observations and studies are needed to confirm causality, and pre-use risk explanations to patients are advisable.
Authors
- Rihan Wu
- Ling Chen (ORCID: https://orcid.org/0000-0001-9639-2691)
- Z. Wang (ORCID: https://orcid.org/0000-0002-0928-2070)
- Yu Bai (ORCID: https://orcid.org/0000-0002-7577-6001)
- Yihui Liu (ORCID: https://orcid.org/0000-0002-3716-125X)
- Chunhui Dong
Institutions
- Ningxia Hui Autonomous Region Peoples Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Ninth Hospital of Nanchang (CN)
- First Hospital of Xi'an (CN)
- The Fourth People's Hospital of Ningxia Hui Autonomous Region (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.3389/fonc.2025.1669407
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Wu Jieping Medical Foundation